{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"GENB","limit":50},"count":18,"signals":[{"ticker":"GENB","company":"Generate Biomedicines, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":30,"context":"dosing regimen. We are currently enrolling patients in two parallel global Phase 3 clinical trials for GB-0895 initiated in December 2025 (SOLAIRIA-1 and SOLAIRIA-2) for severe asthma, with full enrollment expected by the first half of 2028. The first patient was dosed in our SOLAIRIA-1 Phase 3 clinical trial on January 26, 2026. We intend to develop GB-0895 as a biologic-device combination product","filed_date":"2026-02-23","accession":"0001193125-26-062362","full_text":"https://origin.rootz.global/static/filing/0001193125-26-062362.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GENB","company":"Generate Biomedicines, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":77,"context":"nical and clinical trials of our product candidates may be delayed, and certain programs may never advance in the clinic or may be more costly to conduct than we anticipate, any of which would have a material adverse impact on our Generate Platform or our business. • We are currently enrolling patients in clinical trials for GB-0895 globally and may in the future conduct clinical trials for other product candidat","filed_date":"2026-02-23","accession":"0001193125-26-062362","full_text":"https://origin.rootz.global/static/filing/0001193125-26-062362.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GENB","company":"Generate Biomedicines, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":55,"context":"s amended from time to time, the “Amgen Collaboration Agreement”), and, in connection therewith, we received a non-refundable upfront payment of $50.0 million in January 2022, an equity investment of $25.0 million in October 2023 from the sale to Amgen of our Series C preferred stock, an additional upfront payment of $5.0 million in December 2023 in connection with an amendment to the Amgen Collaboration Agree","filed_date":"2026-02-23","accession":"0001193125-26-062362","full_text":"https://origin.rootz.global/static/filing/0001193125-26-062362.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GENB","company":"Generate Biomedicines, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":29,"context":"dosing regimen. We are currently enrolling patients in two parallel global Phase 3 clinical trials for GB-0895 initiated in December 2025 (SOLAIRIA-1 and SOLAIRIA-2) for severe asthma, with full enrollment expected by the first half of 2028. The first patient was dosed in our SOLAIRIA-1 Phase 3 clinical trial on January 26, 2026. We intend to develop GB-0895 as a biologic-device combination product","filed_date":"2026-02-04","accession":"0001193125-26-037799","full_text":"https://origin.rootz.global/static/filing/0001193125-26-037799.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GENB","company":"Generate Biomedicines, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":77,"context":"nical and clinical trials of our product candidates may be delayed, and certain programs may never advance in the clinic or may be more costly to conduct than we anticipate, any of which would have a material adverse impact on our Generate Platform or our business. • We are currently enrolling patients in clinical trials for GB-0895 globally and may in the future conduct clinical trials for other product candidat","filed_date":"2026-02-04","accession":"0001193125-26-037799","full_text":"https://origin.rootz.global/static/filing/0001193125-26-037799.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GENB","company":"Generate Biomedicines, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":46,"context":"s amended from time to time, the “Amgen Collaboration Agreement”), and, in connection therewith, we received a non-refundable upfront payment of $50.0 million in January 2022, an equity investment of $25.0 million in October 2023 from the sale to Amgen of our Series C preferred stock, an additional upfront payment of $5.0 million in December 2023 in connection with an amendment to the Amgen Collaboration Agree","filed_date":"2026-02-04","accession":"0001193125-26-037799","full_text":"https://origin.rootz.global/static/filing/0001193125-26-037799.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GENB","company":"Generate Biomedicines, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"her product candidates; the number and scope of additional preclinical and clinical programs we decide to pursue, and the number of product candidates we decide to develop further; our successful enrollment in and completion of clinical trials; our ability to commercialize products, if and when approved, whether alone or in collaboration with others; third-party maintaining existing, or arranging for","filed_date":"2026-08-06","accession":"0001193125-26-336437","full_text":"https://origin.rootz.global/static/filing/0001193125-26-336437.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GENB","company":"Generate Biomedicines, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":77,"context":"nical and clinical trials of our product candidates may be delayed, and certain programs may never advance in the clinic or may be more costly to conduct than we anticipate, any of which would have a material adverse impact on The Generate Platform or our business. We are currently enrolling patients in clinical trials for GB-0895 globally and may in the future conduct clinical trials for other product candidates outsid","filed_date":"2026-08-06","accession":"0001193125-26-336437","full_text":"https://origin.rootz.global/static/filing/0001193125-26-336437.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GENB","company":"Generate Biomedicines, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":48,"match_count":6,"context":"of such written request) that: (a) such proposed nominee is not and will not become party to any agreement, arrangement or understanding with any person or entity as to how such proposed nominee, if elected as a director of the Corporation, will act or vote on any issue or question (a “Voting Commitment”) that has not been disclosed to the Corporation in the questionnaire described in clause (v) herein;","filed_date":"2026-03-02","accession":"0001193125-26-085780","full_text":"https://origin.rootz.global/static/filing/0001193125-26-085780.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GENB","company":"Generate Biomedicines, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":28,"match_count":1,"context":"existing collaboration partners or that our Generate Platform will achieve adequate market acceptance among new collaboration partners. Any failure to increase penetration in our existing markets or new markets would adversely affect our ability to improve our operating results from our collaboration, partnership and licensing strategy. 53 All of the risks relating to product development, regulatory approv","filed_date":"2026-02-23","accession":"0001193125-26-062362","full_text":"https://origin.rootz.global/static/filing/0001193125-26-062362.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GENB","company":"Generate Biomedicines, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":28,"match_count":1,"context":"existing collaboration partners or that our Generate Platform will achieve adequate market acceptance among new collaboration partners. Any failure to increase penetration in our existing markets or new markets would adversely affect our ability to improve our operating results from our collaboration, partnership and licensing strategy. All of the risks relating to product development, regulatory approval","filed_date":"2026-02-04","accession":"0001193125-26-037799","full_text":"https://origin.rootz.global/static/filing/0001193125-26-037799.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GENB","company":"Generate Biomedicines, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":16,"match_count":2,"context":"mpetition for our biologic product candidates, if approved. The approval of a biosimilar of our product candidate could have a material adverse impact on our business due to increased competition and pricing pressure. In the European Union, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic","filed_date":"2026-08-06","accession":"0001193125-26-336437","full_text":"https://origin.rootz.global/static/filing/0001193125-26-336437.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GENB","company":"Generate Biomedicines, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":16,"match_count":2,"context":"rangements. In December 2021, we entered into the Amgen Collaboration Agreement, and, in connection therewith, we received a non-refundable upfront payment of $50.0 million in January 2022, an equity investment of $25.0 million in October 2023 from the sale to Amgen of our Series C convertible preferred stock, an additional upfront payment of $5.0 million in December 2023 in connection with an amendment to the Amgen Collabo","filed_date":"2026-08-06","accession":"0001193125-26-336437","full_text":"https://origin.rootz.global/static/filing/0001193125-26-336437.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GENB","company":"Generate Biomedicines, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":13,"match_count":1,"context":"existing collaboration partners or that The Generate Platform will achieve adequate market acceptance among new collaboration partners. Any failure to increase penetration in our existing markets or new markets would adversely affect our ability to improve our operating results from our collaboration, partnership and licensing strategy. All of the risks relating to product development, regulatory approval","filed_date":"2026-08-06","accession":"0001193125-26-336437","full_text":"https://origin.rootz.global/static/filing/0001193125-26-336437.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GENB","company":"Generate Biomedicines, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":8,"match_count":1,"context":"tions to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative chan","filed_date":"2026-02-23","accession":"0001193125-26-062362","full_text":"https://origin.rootz.global/static/filing/0001193125-26-062362.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GENB","company":"Generate Biomedicines, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":8,"match_count":1,"context":"ns to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. 74 We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative chan","filed_date":"2026-02-04","accession":"0001193125-26-037799","full_text":"https://origin.rootz.global/static/filing/0001193125-26-037799.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GENB","company":"Generate Biomedicines, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"get collaboration, Novartis has advanced a biologic designed with The Generate Platform into its preclinical pipeline for further development. This marks the first time a biologic engineered using an AI-enabled platform has reached this stage. The Phase 1 study evaluating GB-5267, an IL-18 armored MUC16 CAR T for patients with advanced, platinum-resistant ovarian cancer, which Generate is conducting in collaboratio","filed_date":"2026-08-06","accession":"0001193125-26-336462","full_text":"https://origin.rootz.global/static/filing/0001193125-26-336462.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GENB","company":"Generate Biomedicines, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"& Participants Population: Physician-diagnosed COPD ≥12 months on ≥1 maintenance inhaler with at least 1 maintenance inhaler (e.g., LABA and/or LAMA ICS) for ≥3 months before enrollment Post-BD FEV₁/FVC <0.70 and FEV₁ 40–85% predicted BEC ≥200 cells/L CAT ≥10 ≥10 pack-year current/former smokers Participant Dosing: (3:1 randomization), (N","filed_date":"2026-08-26","accession":"0001193125-26-365556","full_text":"https://origin.rootz.global/static/filing/0001193125-26-365556.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"83d250a07bce8b100340c525a03d077d74d0ae072338ad6adcf4b27b5d1ebc76","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"11a011d3ac164e96779de9b28dd65d0486ca7c39b8563dce0bf9eb8372bd069d","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":38,"hourly_limit":500,"remaining":462,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}